Peter Lawson
Stock Analyst at Barclays
(1.40)
# 3,597
Out of 5,102 analysts
99
Total ratings
39.53%
Success rate
-10.59%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Maintains: Overweight | $19 → $22 | $20.41 | +7.79% | 5 | Nov 4, 2025 | |
| INCY Incyte | Maintains: Overweight | $90 → $101 | $96.10 | +5.10% | 1 | Oct 29, 2025 | |
| ONC BeOne Medicines AG | Initiates: Overweight | $385 | $320.84 | +20.00% | 1 | Sep 18, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $40 | $33.56 | +19.19% | 1 | Sep 4, 2025 | |
| SDGR Schrödinger | Initiates: Overweight | $25 | $18.13 | +37.89% | 1 | Aug 14, 2025 | |
| REPL Replimune Group | Downgrades: Equal-Weight | $17 → $3 | $9.87 | -69.60% | 4 | Jul 23, 2025 | |
| EXEL Exelixis | Maintains: Equal-Weight | $29 → $40 | $41.39 | -3.36% | 6 | Jul 10, 2025 | |
| MGNX MacroGenics | Maintains: Overweight | $8 → $3 | $1.41 | +112.77% | 9 | May 14, 2025 | |
| FATE Fate Therapeutics | Maintains: Overweight | $10 → $2 | $1.11 | +80.18% | 4 | May 14, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $5 → $10 | $7.00 | +42.86% | 3 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $2.25 | +77.78% | 7 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $22 → $6 | $17.05 | -64.81% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $11 | $10.46 | +5.16% | 1 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $16 | $12.57 | +27.29% | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $7.45 | +101.34% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $14 | $25.14 | -44.31% | 7 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $3 | $1.52 | +97.37% | 5 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $3 | $1.07 | +180.37% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $4 | $1.39 | +187.77% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $60 | $78.51 | -23.58% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $7.79 | +118.23% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $66 | $35.80 | +84.36% | 2 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $19.07 | +62.56% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $9.10 | +42.86% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $1.63 | +206.75% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $4.06 | -13.79% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $136.44 | +167.52% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $27.46 | +67.52% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $450 | $51.12 | +780.28% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $2.56 | +1,657.81% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $58.09 | -22.53% | 2 | Jan 23, 2018 |
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Overweight
Price Target: $19 → $22
Current: $20.41
Upside: +7.79%
Incyte
Oct 29, 2025
Maintains: Overweight
Price Target: $90 → $101
Current: $96.10
Upside: +5.10%
BeOne Medicines AG
Sep 18, 2025
Initiates: Overweight
Price Target: $385
Current: $320.84
Upside: +20.00%
IDEAYA Biosciences
Sep 4, 2025
Initiates: Overweight
Price Target: $40
Current: $33.56
Upside: +19.19%
Schrödinger
Aug 14, 2025
Initiates: Overweight
Price Target: $25
Current: $18.13
Upside: +37.89%
Replimune Group
Jul 23, 2025
Downgrades: Equal-Weight
Price Target: $17 → $3
Current: $9.87
Upside: -69.60%
Exelixis
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $29 → $40
Current: $41.39
Upside: -3.36%
MacroGenics
May 14, 2025
Maintains: Overweight
Price Target: $8 → $3
Current: $1.41
Upside: +112.77%
Fate Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $10 → $2
Current: $1.11
Upside: +80.18%
Karyopharm Therapeutics
May 13, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $7.00
Upside: +42.86%
May 12, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $2.25
Upside: +77.78%
May 8, 2025
Maintains: Underweight
Price Target: $22 → $6
Current: $17.05
Upside: -64.81%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $11
Current: $10.46
Upside: +5.16%
May 2, 2025
Maintains: Overweight
Price Target: $32 → $16
Current: $12.57
Upside: +27.29%
May 1, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $7.45
Upside: +101.34%
Apr 23, 2025
Maintains: Overweight
Price Target: $29 → $14
Current: $25.14
Upside: -44.31%
Apr 2, 2025
Maintains: Equal-Weight
Price Target: $11 → $3
Current: $1.52
Upside: +97.37%
Mar 7, 2025
Maintains: Overweight
Price Target: $14 → $3
Current: $1.07
Upside: +180.37%
Feb 27, 2025
Maintains: Overweight
Price Target: $9 → $4
Current: $1.39
Upside: +187.77%
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $78.51
Upside: -23.58%
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $7.79
Upside: +118.23%
Aug 9, 2024
Maintains: Overweight
Price Target: $92 → $66
Current: $35.80
Upside: +84.36%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $19.07
Upside: +62.56%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $9.10
Upside: +42.86%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $1.63
Upside: +206.75%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $4.06
Upside: -13.79%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $136.44
Upside: +167.52%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $27.46
Upside: +67.52%
Mar 4, 2020
Initiates: Overweight
Price Target: $450
Current: $51.12
Upside: +780.28%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $2.56
Upside: +1,657.81%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $58.09
Upside: -22.53%